AMICUS THERAPEUTICS INC (FOLD) Fundamental Analysis & Valuation

NASDAQ:FOLD • US03152W1099

Current stock price

14.385 USD
+0.02 (+0.1%)
Last:

This FOLD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. FOLD Profitability Analysis

1.1 Basic Checks

  • In the past year FOLD has reported negative net income.
  • In the past year FOLD had a positive cash flow from operations.
  • In the past 5 years FOLD always reported negative net income.
  • FOLD had negative operating cash flow in 4 of the past 5 years.
FOLD Yearly Net Income VS EBIT VS OCF VS FCFFOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -2.85%, FOLD belongs to the top of the industry, outperforming 87.07% of the companies in the same industry.
  • FOLD has a Return On Equity of -9.89%. This is amongst the best in the industry. FOLD outperforms 86.68% of its industry peers.
  • With an excellent Return On Invested Capital value of 3.83%, FOLD belongs to the best of the industry, outperforming 90.35% of the companies in the same industry.
Industry RankSector Rank
ROA -2.85%
ROE -9.89%
ROIC 3.83%
ROA(3y)-9.83%
ROA(5y)-17.97%
ROE(3y)-44.48%
ROE(5y)-81.46%
ROIC(3y)N/A
ROIC(5y)N/A
FOLD Yearly ROA, ROE, ROICFOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • The Operating Margin of FOLD (5.44%) is better than 89.58% of its industry peers.
  • With an excellent Gross Margin value of 88.50%, FOLD belongs to the best of the industry, outperforming 90.35% of the companies in the same industry.
  • FOLD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.44%
PM (TTM) N/A
GM 88.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y0.1%
FOLD Yearly Profit, Operating, Gross MarginsFOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. FOLD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), FOLD is destroying value.
  • Compared to 1 year ago, FOLD has more shares outstanding
  • FOLD has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, FOLD has an improved debt to assets ratio.
FOLD Yearly Shares OutstandingFOLD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
FOLD Yearly Total Debt VS Total AssetsFOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 1.27, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of FOLD (1.27) is better than 63.13% of its industry peers.
  • FOLD has a debt to FCF ratio of 13.15. This is a negative value and a sign of low solvency as FOLD would need 13.15 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 13.15, FOLD belongs to the best of the industry, outperforming 90.73% of the companies in the same industry.
  • A Debt/Equity ratio of 1.43 is on the high side and indicates that FOLD has dependencies on debt financing.
  • FOLD has a worse Debt to Equity ratio (1.43) than 77.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 13.15
Altman-Z 1.27
ROIC/WACC0.43
WACC8.91%
FOLD Yearly LT Debt VS Equity VS FCFFOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 2.84 indicates that FOLD has no problem at all paying its short term obligations.
  • The Current ratio of FOLD (2.84) is worse than 66.41% of its industry peers.
  • FOLD has a Quick Ratio of 1.88. This is a normal value and indicates that FOLD is financially healthy and should not expect problems in meeting its short term obligations.
  • FOLD's Quick ratio of 1.88 is on the low side compared to the rest of the industry. FOLD is outperformed by 76.64% of its industry peers.
Industry RankSector Rank
Current Ratio 2.84
Quick Ratio 1.88
FOLD Yearly Current Assets VS Current LiabilitesFOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. FOLD Growth Analysis

3.1 Past

  • FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.33%, which is quite impressive.
  • The Revenue has grown by 20.05% in the past year. This is a very strong growth!
  • FOLD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.44% yearly.
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)20.05%
Revenue growth 3Y24.43%
Revenue growth 5Y19.44%
Sales Q2Q%23.72%

3.2 Future

  • Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 107.92% on average per year.
  • The Revenue is expected to grow by 18.18% on average over the next years. This is quite good.
EPS Next Y534.7%
EPS Next 2Y230.38%
EPS Next 3Y175.47%
EPS Next 5Y107.92%
Revenue Next Year18.91%
Revenue Next 2Y18.63%
Revenue Next 3Y19.2%
Revenue Next 5Y18.18%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
FOLD Yearly Revenue VS EstimatesFOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
FOLD Yearly EPS VS EstimatesFOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. FOLD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 44.12 indicates a quite expensive valuation of FOLD.
  • Based on the Price/Forward Earnings ratio, FOLD is valued cheaply inside the industry as 90.54% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, FOLD is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 44.12
FOLD Price Earnings VS Forward Price EarningsFOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 89.58% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, FOLD is valued cheaply inside the industry as 91.12% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 151.29
EV/EBITDA 108
FOLD Per share dataFOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as FOLD's earnings are expected to grow with 175.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y230.38%
EPS Next 3Y175.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FOLD Dividend Analysis

5.1 Amount

  • FOLD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FOLD Fundamentals: All Metrics, Ratios and Statistics

AMICUS THERAPEUTICS INC

NASDAQ:FOLD (3/17/2026, 11:11:02 AM)

14.385

+0.02 (+0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20
Earnings (Next)04-29
Inst Owners101.15%
Inst Owner Change1.99%
Ins Owners0.55%
Ins Owner Change-8.02%
Market Cap4.52B
Revenue(TTM)634.21M
Net Income(TTM)-27.11M
Analysts71.43
Price Target15.81 (9.91%)
Short Float %6.25%
Short Ratio2.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.92%
Min EPS beat(2)-94.35%
Max EPS beat(2)52.51%
EPS beat(4)2
Avg EPS beat(4)-6.54%
Min EPS beat(4)-94.35%
Max EPS beat(4)52.51%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.26%
Min Revenue beat(2)0.02%
Max Revenue beat(2)0.49%
Revenue beat(4)3
Avg Revenue beat(4)-1.5%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)5
Avg Revenue beat(8)-0.57%
Revenue beat(12)8
Avg Revenue beat(12)-0.07%
Revenue beat(16)10
Avg Revenue beat(16)-0.84%
PT rev (1m)0%
PT rev (3m)-5.8%
EPS NQ rev (1m)20.82%
EPS NQ rev (3m)27.46%
EPS NY rev (1m)0%
EPS NY rev (3m)19.01%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)-1.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 44.12
P/S 7.12
P/FCF 151.29
P/OCF 136.24
P/B 16.47
P/tB 72.22
EV/EBITDA 108
EPS(TTM)-0.08
EYN/A
EPS(NY)0.33
Fwd EY2.27%
FCF(TTM)0.1
FCFY0.66%
OCF(TTM)0.11
OCFY0.73%
SpS2.02
BVpS0.87
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.85%
ROE -9.89%
ROCE 4.84%
ROIC 3.83%
ROICexc 6.51%
ROICexgc 13.18%
OM 5.44%
PM (TTM) N/A
GM 88.5%
FCFM 4.71%
ROA(3y)-9.83%
ROA(5y)-17.97%
ROE(3y)-44.48%
ROE(5y)-81.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y0.1%
F-Score4
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 13.15
Debt/EBITDA 9.36
Cap/Depr 44.18%
Cap/Sales 0.52%
Interest Coverage 0.79
Cash Conversion 79.01%
Profit Quality N/A
Current Ratio 2.84
Quick Ratio 1.88
Altman-Z 1.27
F-Score4
WACC8.91%
ROIC/WACC0.43
Cap/Depr(3y)60.08%
Cap/Depr(5y)62.67%
Cap/Sales(3y)1.02%
Cap/Sales(5y)1.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y534.7%
EPS Next 2Y230.38%
EPS Next 3Y175.47%
EPS Next 5Y107.92%
Revenue 1Y (TTM)20.05%
Revenue growth 3Y24.43%
Revenue growth 5Y19.44%
Sales Q2Q%23.72%
Revenue Next Year18.91%
Revenue Next 2Y18.63%
Revenue Next 3Y19.2%
Revenue Next 5Y18.18%
EBIT growth 1Y1.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year142.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y179.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y197.8%
OCF growth 3YN/A
OCF growth 5YN/A

AMICUS THERAPEUTICS INC / FOLD Fundamental Analysis FAQ

What is the fundamental rating for FOLD stock?

ChartMill assigns a fundamental rating of 4 / 10 to FOLD.


What is the valuation status for FOLD stock?

ChartMill assigns a valuation rating of 5 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.


Can you provide the profitability details for AMICUS THERAPEUTICS INC?

AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.


What is the expected EPS growth for AMICUS THERAPEUTICS INC (FOLD) stock?

The Earnings per Share (EPS) of AMICUS THERAPEUTICS INC (FOLD) is expected to grow by 534.7% in the next year.